Physalin B

Synonyms: 酸浆苦味B
Physalin B 是一种具有口服活性的抗炎、抗癌剂,可从酸浆 (Physalis alkekengi L. var. Franchetii) 中分离得到,能抑制 NF-κB、NLRP3 炎性小体、STAT3、PI3K/Akt 和 Hedgehog 信号通路的激活,调控 GSK-3β、p38 MAPK、ERK1/2 和 JNK 的磷酸化水平,促进 NRF2 的核转位,降低促炎细胞因子和因子的水平,诱导线粒体活性氧 (mito-ROS) 生成、细胞凋亡 (Apoptosis)、G2/M 期细胞周期阻滞和不完全自噬 (Autophagy),改变细胞骨架结构并减轻氧化应激,降低癌细胞活力,改善肝肺组织损伤并减轻肝纤维化,可用于溃疡性结肠炎、乳腺癌、急性肺损伤、结肠癌、非酒精性脂肪性肝炎、肝纤维化、肺癌、胰腺癌、淋巴瘤、卵巢癌、肉瘤和白血病的相关研究。
产品编号: MS-S92354 纯度: 97.20% CAS No.: 23133-56-4 分子式: C28H30O9 分子量: 510.53
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价

产品描述

Physalin B 是一种具有口服活性的抗炎、抗癌剂,可从酸浆 (Physalis alkekengi L. var. Franchetii) 中分离得到,能抑制 NF-κB、NLRP3 炎性小体、STAT3、PI3K/Akt 和 Hedgehog 信号通路的激活,调控 GSK-3β、p38 MAPK、ERK1/2 和 JNK 的磷酸化水平,促进 NRF2 的核转位,降低促炎细胞因子和因子的水平,诱导线粒体活性氧 (mito-ROS) 生成、细胞凋亡 (Apoptosis)、G2/M 期细胞周期阻滞和不完全自噬 (Autophagy),改变细胞骨架结构并减轻氧化应激,降低癌细胞活力,改善肝肺组织损伤并减轻肝纤维化,可用于溃疡性结肠炎、乳腺癌、急性肺损伤、结肠癌、非酒精性脂肪性肝炎、肝纤维化、肺癌、胰腺癌、淋巴瘤、卵巢癌、肉瘤和白血病的相关研究。

生物实验数据

生物活性 Physalin B is an orally active anti-inflammatory and anticancer agent isolated from Physalis alkekengi L. var. Franchetii that inhibits the activation of NF-κB, NLRP3 inflammasome, STAT3, PI3K/Akt and Hedgehog signaling pathways, modulates the phosphorylation levels of GSK-3β, p38 MAPK, ERK1/2 and JNK, promotes NRF2 nuclear translocation, reduces the levels of pro-inflammatory cytokines and factors, induces mitochondrial reactive oxygen species (mito-ROS) production, apoptosis, G2/M cell cycle arrest and incomplete autophagy, alters cytoskeletal structure and alleviates oxidative stress, decreases cancer cell viability, ameliorates hepatic and pulmonary tissue injury and attenuates liver fibrosis, and can be used for research related to ulcerative colitis, breast cancer, acute lung injury, colon cancer, non-alcoholic steatohepatitis, liver fibrosis, lung cancer, pancreatic cancer, lymphoma, ovarian cancer, sarcoma and leukemia.
IC50 & Target

NLRP3 inflammasome

 

GSK-3β

 

STAT3

 

ERK1

 

ERK2

 

体外研究
(In Vitro)

Physalin B (0.25-16.0 µM; 24 h) 在作用 24 h 后,浓度高达 1.0 µM 时对 RAW 264.7 细胞无细胞毒性,但在浓度 ≥2.0 µM 时会诱导显著的浓度依赖性细胞毒性。
Physalin B (0.25-1.0 µM; 2 h pre-incubation, followed by 24 h co-incubation with 1 µg/mL LPS) 可显著抑制 LPS 诱导的 RAW 264.7 细胞中 TNF-α、IL-6 和 IL-1β 的产生。
Physalin B (0.63-40 μM; 12-72 h) 可呈浓度和时间依赖性降低 MCF-7、MDA-MB-231 和 T-47D 细胞的活力,在 40 μM 作用 24 h 后细胞近乎完全死亡。
Physalin B (2.5-10 μM; 48 h) 可将 MCF-7 细胞的凋亡率分别提升至 16.4%、21.6% 和 35.4%。
Physalin B (0.31-10 μM; 72 h) 可强效抑制 HCT116 细胞的活力,其 IC50 为 1.35 μM。
Physalin B (2.5-10 μmol/L; 12-36 h) 可通过促进固缩、凋亡小体形成以及 PARP 和 caspase-3 的切割,在 2.5、5 和 10 μmol/L 浓度下作用 12-36 h 诱导 HCT116 细胞凋亡。
Physalin B (0.25-40 μM; 48 h) 不影响人肝细胞 L02 的活力。
Physalin B (0.25-1 μM; 48 h) 可呈剂量依赖性减少游离脂肪酸诱导的 L02 肝细胞内的脂质积累。
Physalin B (0.25-1 μM; 48 h) 可呈剂量依赖性降低游离脂肪酸 (FFA) 诱导的 L02 细胞内的 ROS 水平。
Physalin B (2.5-5 μM; 30 min) 可抑制 TNFα 诱导的 293T-NF-κB 细胞中 NF-κB 的激活,在 5 μM 浓度下观察到最大 85% 的抑制率。
Physalin B (孵育 24 h) 可降低 LX-2 细胞活力,其 IC50 约为 5 μM。

Cell Viability Assay

Cell Line: mouse monocyte-macrophage RAW 264.7 cells
Concentration: 0.25-16.0 µM
Incubation Time: 24 h
Result: Showed no cytotoxicity (cell viability unchanged relative to control) at concentrations of 0.25, 0.5, and 1.0 µM after 24 h.
Reduced cell viability to 88.50% at 2.0 µM.
Increased cytotoxicity significantly with higher concentrations (4.0, 8.0, 16.0 µM), leading to progressively lower cell survival rates.

ELISA Assay

Cell Line: LPS-stimulated mouse monocyte-macrophage RAW 264.7 cells
Concentration: 0.25-1.0 µM
Incubation Time: 2 h pre-incubation, followed by 24 h co-incubation with 1 µg/mL LPS
Result: Significantly inhibited the LPS-induced release of TNF-α, IL-6, and IL-1β at all tested concentrations, with statistically significant reductions (P < 0.01 to P < 0.001) relative to the LPS-only model group.

Cell Viability Assay

Cell Line: MCF-7, MDA-MB-231, T-47D
Concentration: 0.63-40 μM
Incubation Time: 12 h, 24 h, 48 h, 72 h
Result: Caused less than 20% cell death across all three cell lines at concentrations below 2.5 μM even after 72 h.
Reduced cell viability in a concentration- and time-dependent manner at 2.5-40 μM.
Reduced MCF-7 cell viabilities to 71.8% (12 h), 52.0% (24 h), 43.0% (48 h), 31.8% (72 h) at 20 μM.
Reduced MDA-MB-231 cell viabilities to 78.7% (12 h), 36.2% (24 h), 28.0% (48 h), 33.2% (72 h) at 20 μM.
Reduced T-47D cell viabilities to 85.3% (12 h), 29.9% (24 h), 16.5% (48 h), 10.3% (72 h) at 20 μM.
Nearly completely killed all three cell lines at 40 μM after 24 h or longer incubation.

Apoptosis Analysis

Cell Line: MCF-7
Concentration: 2.5-10 μM
Incubation Time: 48 h
Result: Increased the apoptotic rate of MCF-7 cells in a concentration-dependent manner: from baseline to 16.4% (2.5 μM), 21.6% (5 μM), and 35.4% (10 μM).

Apoptosis Analysis

Cell Line: human HCT116 colon cancer cells
Concentration: 2.5-10 μmol/L (nuclear staining: 5-10 μmol/L; Western blot: 2.5-10 μmol/L)
Incubation Time: 12-36 h (nuclear staining: 24 h; Western blot: 12-36 h)
Result: Induced pyknosis and apoptotic body formation at 5 and 10 μmol/L after 24 h.
Dose- and time-dependently induced cleavage of PARP and caspase-3, with detectable cleavage starting at 12 h for 10 μmol/L, and increasing at 24 and 36 h across all tested concentrations.
体内研究
(In Vivo)

Physalin B (10-20 mg/kg;腹腔注射) 可通过改善临床症状、减轻结肠损伤、恢复免疫器官功能及抑制多条炎症信号通路 (NF-κB、STAT3、β-arrestin1、NLRP3 炎症小体),显著缓解 DSS 诱导的 BALB/c 小鼠急性溃疡性结肠炎。
Physalin B (15 mg/kg;灌胃;每日;连续 7 天) 可通过激活 PI3K/Akt 通路抑制 NF-κB 和 NLRP3 信号传导、减少炎性细胞因子产生并抑制肺组织细胞凋亡,从而保护小鼠免受 LPS 诱导的急性肺损伤。
Physalin B (3.25-600 mg/kg;口服;每日;2-4 周) 可通过激活自噬及 P62-KEAP1-NRF2 抗氧化通路,呈剂量依赖性改善雄性 C57BL/6J 小鼠中 MCD 诱导的非酒精性脂肪性肝炎 (NASH);其中 30 mg/kg 剂量对肝损伤、脂质蓄积、炎症及氧化应激的抑制作用最强,且剂量高达 600 mg/kg 时未观察到毒性。
Physalin B (腹腔注射;1-5 mg/kg;隔日一次;持续 4 周) 可减轻 CCl4 (MS-X51453) 诱导的雄性 C57BL/6J 小鼠肝纤维化,降低胶原沉积水平、肝损伤标志物水平及纤维化相关基因的表达。
Physalin B (1-5 mg·kg−1;腹腔注射;隔日一次;共 14 天) 可改善雄性 C57BL/6J 小鼠中胆管结扎诱导的肝损伤与纤维化,减轻病理损伤、胶原沉积及纤维化标志物的表达。

Animal Model: BALB/c (male, 20 g)
Dosage: 10 mg/kg; 20 mg/kg
Administration: i.p.
Result: Significantly reversed DSS-induced colon shortening, with the 20 mg/kg dose showing greater efficacy than positive control SASP.
Significantly prevented body weight loss in DSS-treated mice by day 7.
Significantly reduced the DAI scores of DSS-treated mice, indicating improved disease symptoms.
Significantly alleviated DSS-induced colonic pathological damage (including epithelial erosion, crypt loss, and immune cell infiltration) and reduced histological scores, with the 20 mg/kg dose showing stronger efficacy than SASP.
Significantly inhibited elevated colonic MPO activity in DSS-treated mice, reducing inflammatory cell infiltration.
Significantly reversed DSS-induced splenomegaly (reduced spleen coefficient) and thymus atrophy (increased thymus coefficient), restoring immune organ function.
Significantly reduced elevated colonic levels of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in DSS-treated mice, with the 20 mg/kg dose showing stronger efficacy than SASP.
Significantly suppressed DSS-induced activation of the NF-κB pathway, as measured by reduced phosphorylation of NF-κB p65 and IκBα.
Significantly suppressed DSS-induced activation of the STAT3 pathway, as measured by reduced phosphorylation of STAT3.
Significantly reduced DSS-induced upregulation of β-arrestin1 protein levels in colon tissue.
Significantly suppressed DSS-induced activation of the NLRP3 inflammasome, as measured by reduced protein levels of NLRP3, ASC, and IL-1β.
Animal Model: BALB/c (male, 10-12 weeks old, 20-22 g, LPS-induced septic ALI)
Dosage: 15 mg/kg
Administration: i.g.; daily; 7 days
Result: Significantly reduced LPS-induced inflammatory cell infiltration in lung tissue.
Decreased lung wet/dry weight ratios and myeloperoxidase activity in lung tissue, blood, and bronchoalveolar lavage fluid.
Mitigated LPS-induced alterations in arterial blood gas parameters (pH, HCO3-, Hgb, PCO2, PO2, BE).
Reversed LPS-induced downregulation of anti-apoptotic protein Bcl-2 and upregulation of pro-apoptotic protein Bax.
Reduced LPS-increased caspase-3 and caspase-9 activity in lung tissue.
Significantly attenuated LPS-induced increases in total inflammatory cells, neutrophils, macrophages, and lymphocytes in blood and bronchoalveolar lavage fluid.
Decreased LPS-elevated protein levels of TNF-α, IL-1β, and IL-6 in blood, bronchoalveolar lavage fluid, and lung tissue, as well as their mRNA levels in lung tissue.
Blocked LPS-induced phosphorylation of NF-κB (p65) and IκBα in lung tissue.
Inhibited LPS-upregulated NLRP3, ASC, and IL-1β protein levels and caspase-1 activity, while increasing pro-IL-1β protein levels in lung tissue.
Reversed LPS-induced downregulation of phosphorylated PI3K/Akt in lung tissue.
Had protective effects abolished by co-administration of PI3K inhibitor LY294002, including restored NF-κB and NLRP3 activation and increased inflammatory cell influx in lung tissue.
Animal Model: C57BL/6J (male, 5 weeks old, 20-22 g, NASH induced by MCD diet for 4 weeks)
Dosage: 3.25 mg/kg; 7.5 mg/kg; 15 mg/kg; 30 mg/kg; 300 mg/kg; 600 mg/kg
Administration: p.o.; daily; 4 weeks (for 3.25-30 mg/kg); p.o.; daily; 2 weeks (for 300-600 mg/kg)
Result: Reversed MCD-induced decreases in body weight and significantly reduced the liver-to-body weight ratio at 30 mg/kg dose compared to the MCD model group.
Reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in a dose-dependent manner, with the 30 mg/kg dose showing the strongest reduction.
Decreased hepatic total triglyceride (TG) and total cholesterol (TC) levels in a dose-dependent manner.
Improved liver injury, hepatocyte ballooning, and inflammatory cell infiltration in a dose-dependent manner; significantly reduced the NAFLD Activity Score (NAS) across all doses.
Significantly decreased hepatic mRNA expression of inflammatory cytokines Il-6, Il-1β, and Tnf-α in a dose-dependent manner, and reduced F4/80 mRNA levels.
Reduced hepatic lipid accumulation in a dose-dependent manner, with the 30 mg/kg dose nearly eliminating large lipid droplets.
Increased hepatic LC3-II protein levels and the LC3-II/LC3-I ratio in a dose-dependent manner.
Increased hepatic NRF2 and P62 protein expression in a dose-dependent manner, and upregulated hepatic mRNA expression of NRF2 target genes Nqo-1 and Ho-1 in a dose-dependent manner.
Showed no abnormal clinical signs or pathological changes in heart, liver, spleen, or kidney tissues at 300 mg/kg and 600 mg/kg oral doses for 2 weeks.
Animal Model: C57BL/6J (male, 5 weeks old, 18-20 g, specific-pathogen-free, liver fibrosis induced by CCl4 injection)
Dosage: 1 mg·kg-1; 2.5 mg·kg-1; 5 mg·kg-1
Administration: i.p.; every other day; 4 weeks
Result: Ameliorated CCl4-induced hepatic inflammatory cell infiltration, central venous wall thickening, and fibrous hyperplasia.
Reduced Sirius Red and Masson's trichrome-stained collagen deposition, fibroplasia, and bridging fibrosis.
Decreased elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.
Lowered hepatic hydroxyproline content.
Significantly reduced mRNA expression of fibrogenic genes (α-sma, Col1a1, Tgfβ1, Timp1) as well as protein levels of α-SMA and COL1A1 in liver tissues.
Animal Model: C57BL/6J (male, 5 weeks old, 18-20 g, specific-pathogen-free, liver fibrosis induced by bile duct ligation surgery)
Dosage: 1 mg·kg-1; 2.5 mg·kg-1; 5 mg·kg-1
Administration: i.p.; every other day; 14 days
Result: Ameliorated BDL-induced liver parenchyma necrosis.
Reduced newly formed bile ducts (assessed by CK19 staining).
Decreased Sirius Red and Masson's trichrome-stained collagen deposition.
Lowered liver-to-body weight ratio and elevated serum biochemical markers (including alkaline phosphatase (AKP), γ-glutamyl transpeptidase (γ-GT), total bile acid (TBA), total bilirubin (TBiL)).
Reduced hepatic hydroxyproline content.
Significantly decreased mRNA and protein levels of fibrogenic markers in liver tissues.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 510.53
分子式 C28H30O9
CAS No. 23133-56-4
别名 酸浆苦味B

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.

酸浆苦味B 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础